Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Translational and regulatory challenges for exon skipping therapies.
Aartsma-Rus A, Ferlini A, Goemans N, Pasmooij AM, Wells DJ, Bushby K, Vroom E, Balabanov P. Aartsma-Rus A, et al. Among authors: vroom e. Hum Gene Ther. 2014 Oct;25(10):885-92. doi: 10.1089/hum.2014.086. Hum Gene Ther. 2014. PMID: 25184444 Review.
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C; DMD Care Considerations Working Group. Bushby K, et al. Lancet Neurol. 2010 Jan;9(1):77-93. doi: 10.1016/S1474-4422(09)70271-6. Epub 2009 Nov 27. Lancet Neurol. 2010. PMID: 19945913 Review.
Transition in Duchenne muscular dystrophy: An expert meeting report and description of transition needs in an emergent patient population: (Parent Project Muscular Dystrophy Transition Expert Meeting 17-18 June 2011, Amsterdam, The Netherlands).
Schrans DG, Abbott D, Peay HL, Pangalila RF, Vroom E, Goemans N, Vles JS, Aldenkamp AP, Hendriksen JG; Expert Meeting Participants on Transition and Adulthood in Duchenne Muscular Dystrophy. Schrans DG, et al. Among authors: vroom e. Neuromuscul Disord. 2013 Mar;23(3):283-6. doi: 10.1016/j.nmd.2012.08.009. Epub 2012 Sep 16. Neuromuscul Disord. 2013. PMID: 22989602 No abstract available.
Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational.
McCormack P, Woods S, Aartsma-Rus A, Hagger L, Herczegfalvi A, Heslop E, Irwin J, Kirschner J, Moeschen P, Muntoni F, Ouillade MC, Rahbek J, Rehmann-Sutter C, Rouault F, Sejersen T, Vroom E, Straub V, Bushby K, Ferlini A. McCormack P, et al. Among authors: vroom e. PLoS Curr. 2013 Jan 10;5:ecurrents.md.f90b49429fa814bd26c5b22b13d773ec. doi: 10.1371/currents.md.f90b49429fa814bd26c5b22b13d773ec. PLoS Curr. 2013. PMID: 23330068 Free PMC article.
Biomarkers and surrogate endpoints in Duchenne: meeting report.
Aartsma-Rus A, Ferlini A, Vroom E. Aartsma-Rus A, et al. Among authors: vroom e. Neuromuscul Disord. 2014 Aug;24(8):743-5. doi: 10.1016/j.nmd.2014.03.006. Epub 2014 May 28. Neuromuscul Disord. 2014. PMID: 24951452 No abstract available.
Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy.
Lynn S, Aartsma-Rus A, Bushby K, Furlong P, Goemans N, De Luca A, Mayhew A, McDonald C, Mercuri E, Muntoni F, Pohlschmidt M, Verschuuren J, Voit T, Vroom E, Wells DJ, Straub V. Lynn S, et al. Among authors: vroom e. Neuromuscul Disord. 2015 Jan;25(1):96-105. doi: 10.1016/j.nmd.2014.09.003. Epub 2014 Sep 11. Neuromuscul Disord. 2015. PMID: 25307856 No abstract available.
83 results